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Summary
Chronic thromboembolic pulmonary hypertension
(CTEPH) is a potentially fatal disease, which may occur
as a rare complication after acute pulmonary embolism,
although the exact epidemiology of CTEPH is unknown.
The mechanisms involved in nonresolution of thrombotic
material and scarring of large and/or small pulmonary ar-
teries are unknown; some risk factors have been identi-
fied. To date, CTEPH is still underdiagnosed and under-
treated. The cardinal symptom of CTEPH is dyspnoea on
exertion, but diagnosis is challenging owing to nonspecific
symptoms. Right heart catheterisation is mandatory for the
diagnosis of pulmonary hypertension, followed by sever-
al imaging methods including besides ventilation/perfusion
scan, computed tomography pulmonary angiography and
conventional angiography. Operability assessment by a
multidisciplinary team is crucial for the management in all
CTEPH patients, as pulmonary endarterectomy (PEA) re-
mains the only curative treatment of choice. PEA leads to
substantial improvement of haemodynamics, symptoms,
and life expectancy enabling many patients to lead unre-
stricted lives under sole anticoagulation therapy. For in-
operable patients or those with disease not amenable
to surgery, medical therapy or balloon angioplasty are
emerging treatment options. Owing to the complexity of
CTEPH, the diagnosis and treatment of CTEPH patients is
reserved exclusively to experienced CTEPH centres.
Keywords: chronic thromboembolic pulmonary hyperten-
sion, pulmonary endarterectomy
Introduction
Chronic thromboembolic pulmonary hypertension
(CTEPH), classified in group 4 of pulmonary hypertension
according to ESC/ERS 2015 guidelines [1], is defined as
symptomatic pulmonary hypertension with persistent pul-
monary perfusion defects despite adequate anticoagulation
for 3 to 6 months [2]. The exact epidemiology of CTEPH is
unknown; it is most probably largely underdiagnosed and
therefore undertreated. One of the aims of the present arti-
cle is to increase awareness of this rare disease and demon-
strate how much patients can benefit from modern multi-
modal treatment concepts in expert centres.
Epidemiology and aetiology
An analysis of CTEPH epidemiology showed that in the
USA, Europe and Japan, the crude annual incidence is 3 to
5 cases/100,000 population [2]. The projection model in-
dicated that the incidence of CTEPH will continue to in-
crease over the next decade [2].
Only 50 to 75% of patients new cases diagnosed each
year have a history of acute pulmonary embolism, but in
over a quarter of the cases there is no documented history
of acute pulmonary embolism (data from an international
CTEPH registry covering Canada and countries in Europe)
[3]. Therefore, other risk factors seem to be involved even
in the absence of acute pulmonary embolism.
Identified risk factors for CTEPH are autoimmune and
haematological disorders [4]. Ventriculo-atrial shunts, in-
fected pacemaker leads, splenectomy, prior venous throm-
boembolism (particularly recurrent venous thromboem-
bolism), non-O blood group, presence of lupus
anticoagulant / antiphospholipid antibodies, thyroid re-
placement therapy and a history of malignancy were linked
to CTEPH [5]. The increased risk for patients with malig-
nancies results from the same mechanisms as for the in-
creased risk of thromboembolic events: activation of the
fibrinolytic and coagulation systems, acute-phase reac-
tions, inflammation and cytokine production [6, 7].
CTEPH incidence after PE
The incidence of CTEPH following an episode of acute
pulmonary embolism is highly variable. In eight studies
from Europe and the USA [2, 8–15] (fig. 1), it ranged from
0.1 to 9.1%, with a calculated weighted average of 4%.
Some studies even calculate an incidence of CTEPH af-
ter acute pulmonary embolism of up to 10% [2], whereas
the incidence reported in Switzerland was much lower
(0.79%) [16]. A systematic literature review revealed an
average incidence of around 4% in Europe and the USA,
but up to 14% in Japan [17]. This variance may partly be
explained by the setting of the studies (tertiary versus pri-
mary care) and the detection rate of true CTEPH; howev-
er, other influences such as environmental or genetic fac-
tors cannot be excluded. Some factors have been identified
to be predictors for CTEPH after acute pulmonary em-
bolism, such as large pulmonary emboli at the initial event,
which carry a higher risk for developing CTEPH [7, 18,
19]. Young age, multiple episodes of pulmonary embolism
and elevated pulmonary artery pressure at the time of pul-
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monary embolism, especially a right ventricular systolic
pressure ≥50mmHg [20], are also risk factors.
Even though there is no clear recommendation, echocar-
diographic screening after acute pulmonary embolism
could be considered up to 2 years after the acute event for
patients with high- and intermediate-risk acute pulmonary
embolism [21]. Surveillance programmes after acute pul-
monary embolism are to be considered for patients with
mainly central vessel embolisation, evidence of right ven-
tricle dysfunction, and thrombophilia [22]. They are espe-
cially vital for patients who remain symptomatic 3 months
after the event.
Pathogenesis
The pathogenesis of pulmonary hypertension in CTEPH is
related to multiple mechanisms. Pulmonary vascular alter-
ations may be observed from central pulmonary arteries
to segmental, subsegmental and distal vessels to a varying
degree in individual patients. Thus, CTEPH may predom-
inantly involve persistent organised thrombi and scars in
proximal pulmonary arteries (main, lobar, and segmental)
or small-vessel disease or both (fig. 2) [23]. Nonresolution
with subsequent organisation and fibrosis of residual
thrombotic material impairs blood flow and leads to
CTEPH [18, 19]. The following factors have been related
to failure of thrombus resolution [7]: inflammation and in-
fection; biological and genetic factors; fibrinogen and fib-
rinolytic abnormalities; platelet function; impaired angio-
genesis; small vessel disease.
Figure 1: Proportion of patients who develop chronic thromboem-
bolic pulmonary hypertension (CTEPH) following pulmonary em-
bolism (PE). #: studies followed-up individual patients after PE.
Reproduced with permission of the European Respiratory Society.
Eur Respir Rev. 2017;26(143):160121 [2]. ©ERS 2017.
Figure 2: Resected tissue from patient with chronic thromboem-
bolic pulmonary hypertension.
Inflammation and infection
An inflammatory component in CTEPH pathogenesis is
suspected because of elevated levels of C-reactive protein
(CRP) [24], interleukin (IL)-6, IL-8, interferon-γ-induced
protein (IP)-10, monokine induced by interferon-γ and
macrophage inflammatory protein-1α, which were signifi-
cantly higher compared with age- and sex-matched healthy
controls [25]. Besides this, increased blood-levels of IP-10
(leading to fibroblast migration and activation) and tumour
necrosis factor [26] were reported to be correlated with
CTEPH. In addition, chronic infection (e.g., Staphylococ-
cus aureus) has been detected in endarterectomy speci-
mens of patients with CTEPH [27].
Biological and genetic risk factors
It has been hypothesised that patients with CTEPH have
hypercoagulability. However, protein C, protein S and an-
tithrombin deficiencies, and mutations of factor V and II,
the classical hereditary thrombotic risk factors, are not
more frequent in patients with CTEPH than in healthy
controls [28]. Increased coagulation factors identified in
CTEPH were antiphospholipid antibodies and lupus an-
ticoagulant (higher frequency compared with idiopathic
pulmonary arterial hypertension), and increased levels of
clotting factor VIII [29] and of von Willebrand factor. Mol-
ecular profiling revealed >1600 genes that were expressed
in pulmonary artery endothelial cells from CTEPH patients
differently from normal controls [30].
Fibrinogen and fibrinolytic abnormalities
Abnormal fibrinogen molecules, such as fibrinogen Aα-
Thr312Ala, have been found in the blood of CTEPH pa-
tients [31–33]. Common to all aberrant fibrin character-
istics found in CTEPH patients is their ability to resist
physiological thrombolysis [18, 34].
Platelet function
A prothrombotic state with higher platelet turnover has
been observed in CTEPH patients, which is supported by
thyroid hormone replacement therapy and splenectomy as
known risk factors for CTEPH [3, 5].
Impaired angiogenesis
Impaired angiogenesis and recanalisation of the thrombus
could be involved in the pathophysiology of CTEPH, as
has been indicated by studies in animal models of impaired
thrombus resolution [35, 36].
Small-vessel disease in CTEPH
The initial trigger for developing CTEPH is most probably
the scarring process of thrombi leading to stenosis, webs
and bands completely or nearly completely occluding the
lumen of the large vessels [37, 38]. But some patients de-
velop, in addition to mechanical obstruction of proximal
arteries, a more or less severe pulmonary microvasculopa-
thy (small vessel disease), first described by Moser and
Bloor [39]. Changes similar to those in pulmonary arterial
hypertension are observed in the small vessel compartment
of CTEPH patients [38]. Abnormal endothelial function,
excessive proliferation of smooth muscle cells, migration
of fibroblasts and inhibition of apoptosis in vascular
smooth muscle cells lead to endothelial dysfunction, vas-
cular remodelling, and micro- thrombosis [39]. As in pul-
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monary arterial hypertension, a persistent vasoconstrictive
state, characterised by high levels of plasma endothelin-1
and overexpression of type B endothelin receptors, may
be present in CTEPH patients [21, 40]. The wall of distal
muscular pulmonary arteries (0.1−0.5 mm in diameter) is
affected by this vascular remodelling, which is explained
by redistribution of the pulmonary flow in non-obstructed
pulmonary arteries leading to high pressures and shear
stress, which results into endothelial dysfunction, increas-
ing pulmonary vascular resistance (PVR) and therefore
symptomatic CTEPH [7].
Clinical presentation
The cardinal symptom of CTEPH is dyspnoea on exertion
and patients usually present with progressive exercise in-
tolerance, fatigue or depression [41, 42]; in later stages
exertional syncope and progressive oedema are prevalent
[43]. These symptoms are nonspecific and potentially mis-
leading, especially in the presence of comorbidities such as
chronic obstructive lung disease, deconditioning and obe-
sity [43, 44]. Thus, CTEPH diagnosis is often delayed [3,
41, 42] and patients may see several doctors and are con-
fronted with incorrect diagnoses before the pulmonary hy-
pertension is correctly diagnosed and classified [45]. For
example, a survey conducted in the UK (n = 488) showed
that 44% of patients saw four or more doctors before a cor-
rect pulmonary hypertension diagnosis was made and the
delay from first consultation to diagnosis was 2 or more
years for more than 30% of the patients [45, 46]. This de-
lay reflects a significant challenge in every day practice,
the need for proper education of physicians and early refer-
ral to expert centres.
On clinical examination, accentuation of the pulmonic
component of the second heart sound may be present, as
a result of a flow murmur caused by turbulence in blood
flow through incompletely obstructed pulmonary arteries.
In the later course of the disease exertional syncope and
signs of right ventricular failure develop.
CTEPH diagnosis
According to the 2016 Consensus Conference, transtho-
racic echocardiography is the first tool of assessment after
presentation of a patient with the clinical signs described
above (fig. 3). However, we also want to mention first-
hand tools such as chest radiography and ECG, and the
findings typical for CTEPH:
ECG and pulmonary function testing
P-pulmonale, right bundle branch block, abnormalities of
the T wave in the chest leads and right-axis deviation are
indications of right heart strain [1, 47, 48]. For patients
with dyspnoea and normal flow and volumes on pul-
monary function testing, but a reduced transfer factor for
carbon monoxide, pulmonary vascular disease should be
considered [49–51]. Decreased carbon dioxide levels in
blood gases or end-tidal measures are a recognised feature
of pulmonary arterial hypertension [52]. Those symptoms
of hyperventilation and ineffective ventilation are even
stronger in CTEPH [53]. Central sleep apnoea and
Cheyne-Stokes respiration can be a result of CTEPH and
should always be cause for closer examination [43, 54].
Chest x-ray
Besides distinct right heart enlargement, pronounced pul-
monary artery dilatation is visible on a postero-anterior
chest x-ray (fig. 4). Furthermore, the so-called Hampton
(sign of previous infarction) and Westermark (areas of hy-
poperfusion) signs can be observed.
Echocardiography
Echocardiography is a first screening tool, where the
transtricuspid pressure gradients can be calculated from
peak velocity of the tricuspid valve regurgitation. Further
indirect signs of pulmonary hypertension are right atrial
and right ventricular dilatation and potential compression-
induced D-shaping of the left ventricle, reduced right ven-
tricular contractility, and Doppler flow abnormalities in the
right ventricular outflow tract [1, 43].
Cardiopulmonary exercise testing
For functional assessment and classification of patients
with pulmonary vascular disease, cardiopulmonary exer-
cise testing (CPET) seems to be a promising additional
clinical tool [43]. Hyperventilation in pulmonary arterial
hypertension and CTEPH typically appears as ineffective
ventilation [53–56]. Patients with ineffective ventilation
caused by pulmonary vascular obstruction show elevated
alveolar-capillary gradients of oxygen and carbon dioxide
[53–56] (fig. 5 and fig. 6).
Imaging
Ventilation/perfusion scintigraphy
The initial screening tool to distinguish CTEPH from other
causes of pulmonary hypertension is a ventilation/perfu-
sion (V/Q) scan, which has the advantages of a limited
radiation dose, no need for intravenous contrast agents
and relatively low costs. With 96% sensitivity, a negative
V/Q is the imaging technique of choice for exclusion of
CTEPH. International guidelines still place V/Q as the
first-line imaging methodology in CTEPH (fig. 7) [57] to
rule out chronic pulmonary embolism as a cause of pul-
monary hypertension [58].
Figure 3: CTEPH diagnostic algorithm. Adapted from Wikens H,
Ulrich S, consensus conference Cologne, 2016. CTED = chronic
thromboembolic pulmonary vascular disease; CTEPH = chronic
thromboembolic pulmonary hypertension; PH = pulmonary hyper-
tension
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Computed tomography pulmonary angiography
Whereas computed tomography pulmonary angiography
(CTPA) is widely accepted as imaging technique of choice
for acute pulmonary embolism, its role in CTEPH is less
well defined. Perfect imaging delivery relies on technical
conditions such as short breath hold (3–5 s) acquisition,
thin collimation and thin-slice (≤1 mm) reconstruction and
three-dimensional analysis. Owing to its high sensitivity
and specificity, CTPA has a good potential in detecting
thromboembolic changes at the lobar level (97–100% and
95–100%, respectively) and the segmental level (86–100%
and 93–99%, respectively) [43, 59–61]. One of the main
advantages of computed tomography (CT) in comparison
to digital subtraction angiography is the visualisation of
many more details, such as mediastinal area, lung
parenchyma, collateralisation, and other features that help
to exclude other differential diagnoses.
Typical local vascular characteristics on CT (fig. 8) are:
– Complete obstruction
– Partial filling defects, mostly eccentric (a)
– Organised emboli (b)
– Intravascular bands and webs (c)
– Poststenotic dilatation (d)
– Calcifications
Typical systemic vascular characteristics on CT (fig. 9)
are:
– Enlargement of central pulmonary vessels (a)
– Enlargement and hypertrophy of right ventricle (b)
– Pericardial effusion
– Enlargement of bronchial arteries (c)
– Enlargement of neighbouring vessels
Figure 4: Chest x-ray. Arrow: prominent pulmonary artery. (Courtesy of Prof. T. Frauenfelder.)
Figure 5: Cardiopulmonary exercise testing of a patient with chronic thromboembolic pulmonary hypertension showing fields 4, 6 and 9 of the
Wasserman panel. (a) Elevated slope of minute ventilation (V′E) / carbon dioxide output (V′CO2) ratio showing hyperventilation (field 4); (b) el-
evated ventilator equivalents for oxygen (EQO2) and carbon dioxide (EQCO2) showing ineffective ventilation (field 6); (c) low and decreasing
end-tidal carbon dioxide tension (PETCO2), elevated alveolar-arterial oxygen tension gradient (PA-aO2) and elevated arterial end-tidal carbon
dioxide gradient (Pa-ETCO2) (field 9). Reproduced with permission of the European Respiratory Society. Eur Respir Rev.
2017;26(143):160108 [43]. © ERS 2017. PETO2 = end-tidal oxygen tension; PaO2 = arterial oxygen tension; PaCO2 = arterial carbon dioxide
tension; PO2 = oxygen tension; PCO2 = carbon dioxide tension.
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– Intercostal vessels, mammary artery Furthermore, typical parenchymal characteristics on CT
(fig. 10) are:
Figure 6: Heterogeneous pulmonary perfusion is the hallmark of CTEPH, with progressive CTEPH, nonoccluded arteries tend to narrow (re-
modelling), this reduced extend of blood flow heterogeneity. Reproduced with permission of the European Respiratory society. Eur Respir J.
2012;39(1):119-124 [53]. © ERS 2012.
Figure 7: Ventilation/perfusion (V/Q) scan. In the perfusion images patchy perfusion defects (arrow) unmatched in the ventilation images.
(Courtesy of Prof. T. Frauenfelder.)
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– Mosaic pattern (a)
– Sharp borders
– Unspecific
– Pulmonary infarctions (b)
– Scars irregular, linear, wedge like form, near pleura
– Bronchial dilatation / ipsilateral bronchiectasis (c)
– Localisation correlates with position of affected ves-
sels
Dual-energy computed tomography
The introduction of dual-energy CT (DECT) (fig. 11) per-
mits functional data on lung perfusion (iodine distribution
maps / lung perfusion blood volume images) in addition to
anatomical images [58]. With the processed data, the fol-
lowing images can be generated: conventional grey-scale
images, colour-coded overlays that highlight the iodine
distribution, and virtual nonenhanced images from post-
contrast images by use of iodine-subtraction techniques
[43]. These are reader-independent and rapid tools to quan-
titatively assess regional iodine density, reflecting pul-
Figure 8: Local vascular characteristics on computed tomography. (a) Partial filling defects, mostly eccentric; (b) organised embolism; (c) in-
travascular bands and webs; (d) poststenotic dilatation. (Courtesy of Prof. T. Frauenfelder.)
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monary perfusion, and correlate with a V/Q scan or single
photon emission computed tomography (SPECT) V/Q
scan [62, 63]. Qualitative assessment of less- or under-per-
fused lung areas is comparable to scintigraphy [43, 64, 65],
and might replace V/Q scans in the future.
Positron emission tomography
Distinguishing CTEPH from other conditions mimicking
the disease such as pulmonary artery sarcoma is the prima-
ry role of positron emission tomography (PET). Pulmonary
artery sarcoma and CTEPH distinctively differ in their spe-
cific uptake value (SUVmax) on PET [43]. SUVmax of pul-
monary artery sarcoma is generally approximately three-
fold or more higher than that of thrombi [43, 66].
Digital subtraction angiography
Digital subtraction angiography (DSA) was for a long time
the gold standard for diagnosis and therapy planning in
CTEPH (fig. 12). The morbidity and mortality rates of
invasive angiography are 3.5–6% and 0.2–0.5%, respec-
tively [58, 67, 68], but obviously strongly depend on the
centre’s experience. The use of CTPA is expanding, and
it seems to outperform DSA for detection of CTEPH, as
shown in a comparative study of 24 patients [43, 59]. The
sensitivity of DSA varied from 66% at the main/lobar level
to 76% at segmental level, in contrast to 100% for CTA at
comparable levels. Specificity of both techniques was ex-
cellent (100%), although DSA had a slight advantage over
CTA in depicting subsegmental arteries (DSA 97%; CTA
80%) [43, 59]. One particular advantage is the option for
simultaneous pulmonary artery haemodynamic assessment
during right heart catheterisation. Furthermore, balloon an-
gioplasty is an emerging technique for inoperable CTEPH,
and to this end, traditional angiography has experienced
a renaissance. Rotational angiography and cone beam CT
are emerging techniques for optimised visualisation of in-
traluminal webs and bands.
Figure 9: Systemic vascular characteristics on computed tomography. (a) Enlargement of central pulmonary vessels; (b) enlargement and hy-
pertrophy of right ventricle; (c) enlargement of bronchial arteries. (Courtesy of Prof. T. Frauenfelder.)
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Right heart catheterisation
Assessment of pulmonary haemodynamics by right heart
catheterisation is mandatory for the diagnosis of CTEPH,
with a mean pulmonary artery pressure (mPAP) ≥25 mm
Hg [1] (this threshold will most probably be reduced to ≥20
mmHg as this threshold better reflects the upper limit of
normal), and to exclude postcapillary pulmonary hyperten-
sion with a pulmonary artery wedge pressure ≤15 mm Hg.
Assessing pulmonary haemodynamics during exercise as
multipoint pressure-flow slopes may be especially impor-
tant in chronic thromboembolic pulmonary vascular dis-
ease with a still normal resting mPAP [69]. Correct assess-
ment of the cardiac output by thermodilution or the direct
Fick method is crucial for correctly calculating the pul-
monary vascular resistance (PVR), an important factor in
the assessment of prognosis and risks for surgery [70].
Cardiac magnetic resonance imaging
Over the last decade, magnetic resonance imaging (MRI)
has undergone significant technical improvement, with
faster sequences, shorter acquisition times, larger coverage
and ability to perform functional studies, lung perfusion
imaging, and high-resolution MR pulmonary angiography
(MRPA) [58]. However, the use of MRI is still highly de-
Figure 10: Parenchymal characteristics on computed tomography. (a) Mosaic pattern; (b) pulmonary infarctions; (c) bronchial dilatation / ipsi-
lateral bronchiectasis. (Courtesy of Prof. T. Frauenfelder.)
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pendent on local practice and is not yet fully integrated in
the CTEPH diagnostic algorithm. MRI is suitable for re-
search and for the diagnostic work-up and follow-up of
patients with CTEPH, where it enables both an assess-
ment of the pulmonary arterial obstructive disease and de-
tailed evaluation of right ventricular function or alternative
causes for pulmonary hypertension [58]. There are only
a few comparative studies assessing the accuracy of MRI
in CTEPH. Ley et al. [59] compared CTA, ce-MRA, and
DSA, showing the sensitivity and specificity of MR an-
giography for diagnosing disease at the main/lobar level
to be 83.1% and 98.6%, respectively, and at the segmental
level 87.7% and 98.1%, respectively. Subsegmental arter-
ies were demonstrated in only 75% of cases, compared
with 87% by DSA [43]. Another role of MRI could be as a
Figure 12: Digital subtraction angiography. Pouch-like ending of
pulmonary artery segments (arrow) as well as stenosis and dilated
pulmonary arteries are visualised. (Courtesy of Prof. T. Frauen-
felder.)
follow-up tool after surgery as it can detect non-invasively
changes in parameters reflecting cardiac remodelling and
pulmonary clearance [71].
Prognosis
Pathological haemodynamic parameters at the time of
CTEPH diagnosis negatively impact survival. A mean pul-
monary arterial pressure (mPAP) ≥50 mm Hg is associated
with a 2-year mortality of >80% if untreated and a mPAP
>30 mm Hg with a 3-year mortality of 90% [72].
Once CTEPH is diagnosed and confirmed at an expert
centre, treatment assessment is mandatory. European So-
ciety of Cardiology (ESC) / European Respiratory Society
(ERS) guidelines have defined the clear recommendations
for pulmonary hypertension referral centres (fig. 13) [1].
Figure 13: Recommendations for pulmonary hypertension referral
centres. CTD = connective tissue disease; CTEPH = chronic
thromboembolic pulmonary hypertension; DPAH = drug-induced
pulmonary arterial hypertension; HPAH = heritable pulmonary arte-
rial hypertension; IPAH = idiopathic pulmonary arterial hyperten-
sion; PAH = pulmonary arterial hypertension; PEA = pulmonary
endarterectomy. a Class of recommendation. b Level of evidence. c
Reference(s) supporting recommendations. Reproduced with per-
mission of the European Society of Cardiology & European Respi-
ratory Society©. Eur Respir J. 2015;46(4):903–75 [1].
Figure 11: Dual-energy computed tomography (CT). (a) Contrast-enhanced CT axial reconstruction demonstrating a dilated right atrium, and
narrowing of the pulmonary arteries of the right side by thromboembolic material; (b) contrast-enhanced CT coronary reconstruction with mo-
saic perfusion pattern; (c) dual-energy CT scan showing iodine mapping of unmatched perfusion defects. (Courtesy of Prof. T. Frauenfelder.)
Review article: Biomedical intelligence Swiss Med Wkly. 2018;148:w14702
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 9 of 17
Treatment guidelines
Surgical therapy
The ERS/ESC guidelines [1] recommend pulmonary en-
darterectomy (PEA) as the treatment of choice for patients
with surgically accessible CTEPH. PEA improves pul-
monary hypertension by ameliorating lung ventilation-per-
fusion mismatch, significantly reducing right ventricular
dysfunction and changing pulmonary haemodynamics, re-
stricting retrograde expansion of thromboembolic material,
and preventing arteriopathic changes in the remaining
patent small pulmonary vessels [73] (fig. 14).
In the past, more than a third of patients diagnosed with
CTEPH did not undergo PEA [3], which demonstrates that
treatment in an expert centre and patient selection is cru-
cial.
Patient selection for pulmonary endarterectomy
Operability should be evaluated by an interdisciplinary ex-
pert team including pulmonologists, radiologists and sur-
geons [74]. The severity of the patient’s symptoms and the
severity of pulmonary hypertension and right heart dys-
function, technical challenges, patients’ comorbidities, as
well as the level of expectation for long-term benefits, are
all important factors in the decision-making process [73].
The most important selection criteria are sufficient throm-
boembolic material surgically accessible and a proportion-
al PVR as an indicator of missed extensive distal vascu-
lopathy. However, symptomatic patients should be offered
surgery regardless of the severity of pulmonary hyperten-
sion or right ventricular dysfunction [73]. Thus, neither the
PVR nor the degree of right ventricular dysfunction should
exclude a patient from consideration for surgery [73]. Sur-
gically accessible disease is not clearly defined. Disease lo-
cated proximally in the main, lobar or segmental arteries is
usually amenable for PEA, but experienced CTEPH surgi-
cal teams can operate successfully on more distal disease
with good haemodynamic and functional results [75]. PEA
should therefore be considered in all patients who have
evidence of thromboembolic disease, including those with
more distal disease, as proposed by experienced surgeons
[70, 75–78].
Recent years have brought growing confidence to operate
not only on patients with more severe pulmonary hyper-
Figure 14: CTEPH Treatment algorithm recommendation accord-
ing to consenus conference Cologne. Wikens H et al., consensus
conference Cologne, 2016
tension and more distal obstruction, but also on patients
with chronic thromboembolic pulmonary vascular disease
and normal resting haemodynamics, which potentially re-
veal an inadequate flow-related-pressure increase during
exercise [75]. It has been observed that substantial im-
provements in functional and exercise performance can be
achieved and PEA should be considered for these patients
[1, 75] in order to improve the significant V/Q mismatch,
and eventually prevent chronic changes and development
of secondary vasculopathy.
PEA: the surgical technique
PEA requires specialist training and sophisticated inten-
sive care postoperatively [75]. It is performed via a median
sternotomy for a bilateral approach. Cardiopulmonary by-
pass is installed and the body is cooled to 18‒20°C to allow
deep hypothermic circulatory arrest (DHCA) for provision
of a clear operating field. DHCA is limited to 20-minute
intervals. Usually one period for each side is enough to
complete dissection [75]. In the PEACOG (PEA and COG-
nition) trial [79], the impact of DHCA on cognitive func-
tion at 3 months and 1 year, compared with cerebral per-
fusion during PEA, was investigated. With respect to
cognitive function and postoperative improvement the two
techniques performed equally, indicating that DHCA at
20°C for PEA is safe and well tolerated with careful anaes-
thetic and cardiopulmonary bypass management, and pro-
vides reproducible, excellent results for the lungs and the
brain [75]. Longer circulatory arrest times should be avoid-
ed, as they may be associated with neurological complica-
tions, as suggested by registry results [80].
In order to be able to dissect to the level of segmental
and subsegmental branches, the endarterectomy dissection
plane should be circumferential. PVR is not reduced by a
simple thrombectomy or embolectomy without a true en-
darterectomy [81]. Adequate removal of thromboembolic
material and prevention of perforation of the pulmonary
artery can only be achieved by identification of the correct
surgical plane [75, 82, 83].
After completion of the endarterectomy, the patient is
reperfused and the warming process is started. Depending
on the patient’s body mass, rewarming generally takes ap-
proximately 90 to 120 minutes. The systemic rewarming
period can be conveniently used for other cardiac proce-
dures required, such as coronary artery or mitral or aortic
valve surgery (most common are closure of the foramen
ovale and coronary bypass surgery) [73]. The outcome is
comparable to combined interventions in terms of haemo-
dynamic effects and early mortality. A difference has been
reported in length of intubation, number of complications
and longer hospitalisation [84, 85]. Tricuspid valve repair
is not necessary unless there is an anatomical abnormality,
even though tricuspid valve regurgitation is variable in
these patients and often moderate to severe, as right ven-
tricular remodelling occurs naturally within a few days,
with the return of tricuspid competence [73, 86].
Morbidity and mortality
There are two major well-known complications in the post-
operative course of PEA, even with favourable outcomes
in most patients: residual pulmonary hypertension and
reperfusion pulmonary oedema [74]. Persistently elevated
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pulmonary artery pressure often occurs in combination
with reperfusion lung injury. Both situations can be im-
proved by means of extracorporeal membrane oxygenation
(ECMO): in the case of haemodynamic instability, venoar-
terial ECMO can be used. Cardiac output and gas exchange
are improved as a result of right ventricle off-loading and
reduction of pulmonary artery pressure. In the case of
reperfusion injury alone, conservative therapy or venove-
nous ECMO may be an option.
Acute mortality depends on multiple factors [75], includ-
ing chronicity of disease, CTEPH team experience, pre-
operative PVR, exercise capacity, the patient’s New York
heart Association (NYHA) functional class, comorbidities
and the distribution of the disease [41, 70, 77, 80]. Higher
preoperative PVR may increase mortality [41, 77, 87] (fig.
15). In-hospital mortality is three times higher in patients
with PVR >1200 dyn·s·cm–5 at diagnosis compared with
PVR 400–800 dyn·s·cm–5, as demonstrated by the interna-
tional CTEPH registry [41]. Early postoperative morbidity
and mortality are most often caused by residual pulmonary
hypertension (>500 dyn.s.cm-5) after surgery [73]. At the
University of California San Diego Medical Center, mor-
tality rates were 10.3 and 0.9% in patients with and without
residual pulmonary hypertension, respectively [77]. The
higher the PVR, the higher the gain from PEA surgery, as
these patients have the greatest relative improvement and
the most potential prognostic benefit. Patients with high
PVR >1200 dyn·s·cm–5 with poor right ventricular func-
tion and more distal disease on imaging have the highest
risk [75].
Haemodynamic, functional, and survival outcomes
[75]
Following successful PEA, significant improvement of
functional dyspnoea, NYHA class and 6-minute walk test
(6MWT), increased oxygen uptake, and improvement of
the minute ventilation (V′E) / carbon dioxide output
(V′CO2) ratio (VE:VCO2), as well as a decrease in oxygen
supply necessity have been documented [88, 89]. Average
improvements from PVR 700–800 dyn·s·cm–5 to 250
dyn·s·cm–5 have been experienced [41, 77] following
Figure 15: Effects of pulmonary vascular resistance (PVR) at diag-
nosis on in-hospital and 1-year mortality in patients with chronic
thromboembolic pulmonary hypertension (CTEPH) undergoing
pulmonary endarterectomy. Data from the international CTEPH
registry [41]. * p <0.05 compared with group with PVR >1200
dyn·s·cm-5. Reproduced with permission of the European Respi-
ratory Society. Eur Respir Rev. 2017; 26(143);160111 [75]. ©ERS
2017
surgery, a fall of ∼65%, mPAP (from 46 to 26 mm Hg)
[77] and increase in 6-minute walking distance from 362 to
459 m [41], as well as an improved NYHA functional class
and quality of life after PEA [41, 75, 90]. In the medium
to long term, survival rates of >90% at 1 year, >80% at 5
years, and >70% at 6–10 years have been reported [91–93].
Recent data from the international CTEPH registry report
estimated survival rates of 93% at 1 year, 91% at 2 years,
and 89% at 3 years after PEA; a significant improvement
to the survival rate of patients who did not have PEA [80].
Persistent pulmonary hypertension after PEA [75]
Even after apparently successful PEA, up to 30% of pa-
tients may have persistent (or residual) pulmonary hyper-
tension [94–96]. To date there is no agreed definition be-
cause right heart catheterisation is not routinely performed
in all patients after PEA [76]. The best thresholds correlat-
ing with higher risk of death independent of cause were a
mPAP ≥36 mm Hg and a PVR ≥416 dyn·s·cm–5 (as time-
varying measures), whereas a mPAP ≥38 mm Hg and a
PVR ≥425 dyn·s·cm–5 identified those patients at higher
risk of death caused by CTEPH [75].
However, postoperative pulmonary hypertension does not
seem to affect medium-term survival [75]. A prospective
study from Papworth Hospital (Cambridge, UK) revealed
5-year survival rates that did not differ significantly in pa-
tients discharged with a postoperative mPAP <30 mm Hg
compared with those with mPAP ≥30 mmHg (90.3 and
89.9%, respectively) [97].
Medical treatment can benefit patients with residual pul-
monary hypertension after removal of the mechanical ob-
struction, as suggested by the recent clinical trials with ri-
ociguat in this setting [98–100].
Identification of expert centres for PEA [75]
The first step in the ESC/ERS treatment algorithm is ad-
vice to confirm the diagnosis at a CTEPH expert centre
[1] (fig. 14). There is a potential concern that centres with
limited expertise may offer unlicensed drug treatment or
balloon pulmonary angioplasty (BPA) to patients who are
eligible for, and would benefit more from, PEA [75]. A
CTEPH expert centre should thus have surgeons, experi-
enced BPA interventionists and pulmonologists with broad
experience in pulmonary hypertension available [75], in
particular because the combination of all techniques is de-
veloping as a future direction (table 1). Several approach-
es have already been successfully used, such as intraoper-
ative planned BPA during PEA [101], acute rescue BPA
after failure of PEA [102], or BPA for residual or recurrent
pulmonary hypertension months or years after PEA [103].
Following the international recommendation on expert
centres, Switzerland as a country with 8.4 million inhab-
itants [104] should concentrate treatment of CTEPH pa-
tients in one or two centres in order to comply with interna-
tional quality standards. Since 2015, a CTEPH programme
fulfilling all international requirements can be offered in
Switzerland with the concentration of cases mandatory in
order to perform on a high quality level. The University
Hospital Zurich fulfils all the conditions required and we
have assembled a multidisciplinary team that assesses
every CTEPH patient. Since 2015 we have assessed 62
patients, and we operated on 34 in the first 2 years, a
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resectability rate comparable to international registries
(55%), as was the perioperative mortality of 3% [3]. With
a short median follow-up period of 13 months (range 0–30
months), we have invasive haemodynamic data on 11 pa-
tients with a clear and significant improvement of the
mPAP (fig. 16), but also in NYHA classification and
6MWT (unpublished data).
Under the umbrella of the Swiss Society of Pulmonary Hy-
pertension, a national CTEPH board was initiated at the
beginning of 2018 as a close collaboration between uni-
versity hospitals broadcasting the case discussion to every
centre interested and offering the opportunity to referring
Figure 16: Reduction of mean pulmonary arterial pressure (mPAP)
1 year after pulmonary endarterectomy (Zurich, unpublished data)
physicians to present their cases live and join the discus-
sion (CTEPH@SGPH.ch; CTEPH@usz.ch).
Balloon pulmonary angioplasty
Since 2001, reports have emerged, mainly from Japan, of
innovative BPA for mainly females not eligible for surgery
owing to comorbidities [105–108]. Multiple angioplasty
procedures in single patients were necessary to achieve
a significant reduction of the PVR and the studies were
not randomised-controlled. However, haemodynamic im-
provements reported were impressive and so were im-
provements in the 6-minute walk distance and NYHA/
WHO functional class. In general, lobar and proximal seg-
mental disease is better suited for surgical resection,
whereas distal segmental and subsegmental disease is more
appropriate for BPA [109] (fig. 17).
Many questions remain unresolved about this new inter-
vention, such as patient selection, risk of bleeding, vessel
rupture, restenosis rate and other complications [109]. Data
on long-term results are not yet available [109].
Adverse events during balloon pulmonary angioplasty
[109]
In recent series, BPA periprocedural mortality ranged from
0 to 10% [106–108, 110–114]. The two most common
complications of BPA were reperfusion pulmonary oede-
ma and pulmonary vascular injury, with rare episodes of
vessel perforation or rupture [109]. Despite the advances in
and improvement of the procedure, reperfusion pulmonary
oedema remains a frequent complication of BPA with an
incidence as high as 53 to 60% in some studies [107, 108].
Pulmonary artery perforation or rupture is a serious com-
plication of BPA and is reported in 0 to 7% of procedures
[109]. Thus, this treatment modality should be reserved for
expert centres offering rescue and salvage strategies [109].
As pointed out in the previous paragraphs, the concentra-
tion of BPA also to expert centres is mandatory and again
should be limited to no more than one or two centres in
Switzerland.
Figure 17: Balloon pulmonary angioplasty angiography demonstrating a well-perfused segment of a left sided pulmonary artery segment after
dilatation. (Courtesy of Prof. T. Pfammatter.)
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Medical therapy
Patients with distal CTEPH that is not surgically accessible
or residual pulmonary hypertension after PEA benefit from
medical therapy [37, 74]. CTEPH and pulmonary arterial
hypertension share many pathogenetic features [39, 98,
100, 115]. Thus, medical therapy as used for pulmonary ar-
terial hypertension (PAH-targeted therapy) can be offered
as a therapeutic option for patients with postoperative per-
sistent pulmonary hypertension and patients with inoper-
able CTEPH. This concept is supported by the following
clinical trials: BENEFiT was the first large randomised
controlled trial showing that bosentan given for 6 months
was associated with an unchanged 6-minute walk distance
but a PVR reduced by 24% compared with placebo in pa-
tients with inoperable CTEPH [116].
More recently, clinically relevant primary endpoints could
be reached in the large CHEST-1 trial with the soluble
guanylate cyclase stimulator riociguat, and the CHEST-2
extension trial [98]. After a cautious up-titration schema in
order to avoid systemic vasodilatory effects with hypoten-
sion, patients under riociguat had an improved 6-minute
walk distance by on average 46 m and a reduced PVR
by 31%. In the MERIT trial, the PVR was significantly
reduced by 16%, with improvements in functional class
and walk distance; the improvements were also found in
patients pretreated with phosphodiesterase-5 (PDE-5) in-
hibitors, indicating successful combination therapy also in
patients with distal CTEPH [115].
Oral anticoagulation
Lifelong oral anticoagulation (OAC) is a prerequisite for
every patient with CTEPH regardless of other therapies,
and therapeutic decisions should be considered only after
at least 3 month of OAC [1, 57]. Traditionally, vitamin K
antagonists have been used, although there is no prospec-
tive study of any type of OAC in CTEPH and all data
are derived from recommendations for OAC after acute
pulmonary embolism [117]. In recent years, non-vitamin
K dependent oral anticoagulants that inhibit factor Xa or
prothrombin (so-called novel oral anticoagulants, NOACs)
have increasingly been shown to be as effective as vitamin
K antagonists but with a better safety profile, and are thus
more and more preferentially used to prevent recurrence
after acute pulmonary embolism [57, 118]. Because of the
long experience with vitamin K antagonists, many experts
still recommend them as first-line treatment; however, as
a result of the equal efficacy in the first high-risk phase
after acute pulmonary embolism and the more favourable
profile concerning bleeding events, it seems reasonable to
assume that the favourable risk-benefit profile would per-
sist in the long term and make these NOAC suitable for
life-long treatment in CTEPH after careful patient instruc-
tion about the need not to forget any dose. To date, we still
treat patients with vitamin K antagonists after pulmonary
endarterectomy, but if dose finding is difficult and often off
the targeted range of international normalised ratio (INR)
2.5–3.5, we treat patients with NOACs.
Conclusion
CTEPH and chronic thromboembolic pulmonary vascular
diseases should be diagnosed and treated in expert centres
Table 1: Characteristics of an expert centre. Reproduced with per-
mission of the European Respiratory Society©. Eur Respir Rev.
2017;26 (143):160111 [75].
Extensive experience with cardiothoracic surgery, including proce-
dures requiring DHCA
Excellent pulmonary and cardiac services
Emphasis on pulmonary hypertension
Expert diagnostic imaging
Experienced multidisciplinary team comprising surgeons, radiolo-
gists, anaesthetists, intensivists, nurses, perfusionists, respiratory
therapists and interventionalists, including specialists experienced in
BPA
BPA = balloon pulmonary angioplasty; DHCA = deep hypothermic
circulatory arrest
with multimodal management that has to include evalua-
tion for surgery in every single patient. PEA substantial-
ly improves functional and exercise capacity and haemo-
dynamics, as well as life expectancy. Patients with distal,
surgically inaccessible disease or residual pulmonary hy-
pertension after surgery may substantially improve with
medical therapy. BPA may be a promising option in pa-
tients with subsegmental disease alone or in combination
with surgery and, as all CTEPH treatment modalities,
should only be performed at expert centers. For patient as-
sessment, the Swiss Society of Pulmonary Hypertension
promoted a national CTEPH board which referring physi-
cians can connect to for presentation and discussion of
their cases CTEPH@usz.ch, CTEPH@sgph.ch).
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